People
US CDC Advisory Committee on Immunization Practices Recommends Booster Vaccination with Moderna's COVID-19 Vaccine
22 November 2021 - - The US Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices has voted to recommend the use of a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level for people aged 18 and older under the Emergency Use Authorization (EUA) issued by the US Food and Drug Administration, US-based biotechnology company Moderna, Inc., (NASDAQ: MRNA) said.

The positive vote was unanimous with 11 ACIP members recommending the booster.

The ACIP is comprised of independent health experts. Today's ACIP recommendation follows the FDA's emergency use authorization of a booster dose.

This ACIP recommendation will be forwarded to the director of the CDC and the US Department of Health and Human Services for review and adoption.

The ACIP advises the CDC on the populations and circumstances for which vaccines should be used.

In 10 years since its inception, Moderna has transformed from a science research-stage company advancing programs in the field of messenger RNA, to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across six modalities, a broad intellectual property portfolio in areas including mRNA and lipid nanoparticle formulation, and an integrated manufacturing plant that allows for both clinical and commercial production at scale and at unprecedented speed.

Moderna maintains alliances with a broad range of domestic and overseas government and commercial collaborators, which has allowed for the pursuit of both groundbreaking science and rapid scaling of manufacturing.

Most recently, Moderna's capabilities have come together to allow the authorized use of one of the earliest and most effective vaccines against the COVID-19 pandemic.

Moderna's mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and auto-immune diseases.

Moderna has been named a top biopharmaceutical employer by Science for the past seven years.

Moderna COVID-19 Vaccine is authorized for use under an Emergency Use Authorization for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 18 years of age and older.
Login
Username:

Password: